Their analysis revealed that docetaxel-loaded albumin nanoplatforms achieve superior antitumor efficacy by selectively delivering therapeutic payloads to target tissues, reducing systemic side effects and drug dosage requirements while extending the circulation half-life and improving bioavailability at tumor sites [83]. The gene discussed is ALB; the disease is neoplasm.